ABLS - ETF AI Analysis
Top Page
Abacus FCF Small Cap Leaders ETF (ABLS)
Rating:68Neutral
Price Target:―
Positive Factors
Standout Top Holding
The largest position in the fund has delivered very strong gains this year, providing a meaningful boost to overall performance.
Broad Sector Mix
Holdings spread across health care, industrials, financials, technology, and several smaller sectors help reduce reliance on any single industry.
Moderate Expense Ratio
The fund’s fee is reasonable for a specialized small-cap strategy, allowing investors to keep more of their returns compared with many actively managed products.
Negative Factors
Heavy Single-Stock Concentration
One stock makes up a large share of the portfolio, which increases the impact that any bad news from that company could have on the ETF.
Mixed Performance So Far This Year
Despite a strong recent month, the ETF’s returns over the year to date and the last three months have been weak, showing uneven momentum.
Almost Entirely U.S.-Focused
With nearly all assets invested in U.S. companies, the fund offers little geographic diversification and is highly tied to the U.S. market.
ABLS vs. SPDR S&P 500 ETF (SPY)
AUM1.39M
RegionNorth America
Expense Ratio0.39%
Beta0.71
IssuerAbacus
Inception DateFeb 18, 2025
Dividend YieldN/A
Asset ClassEquity
Index TrackedAbacus FCF Small Cap Leaders Index - Benchmark TR Gross
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume2,156
30 Day Avg. Volume908
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
26.30Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering47
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
ABLS Summary
The Abacus FCF Small Cap Leaders ETF (ABLS) tracks the Abacus FCF Small Cap Leaders Index, focusing on smaller U.S. companies that show strong profits and healthy cash flow. It holds a mix of businesses across health care, industrials, finance, and technology, including names like Collegium Pharmaceutical and Arlo Technologies. Investors might consider ABLS if they want growth potential from small companies while still focusing on financially solid firms and diversifying beyond large, well-known stocks. A key risk is that small-cap shares can be more volatile, so the ETF’s value can move up and down more sharply than the overall market.
How much will it cost me?The Abacus FCF Small Cap Leaders ETF (ABLS) has an expense ratio of 0.39%, meaning you’ll pay $3.90 per year for every $1,000 invested. This is slightly higher than average for passively managed ETFs because it focuses on a niche area of small-cap stocks with strong financial metrics.
What would affect this ETF?The Abacus FCF Small Cap Leaders ETF could benefit from strong growth in the U.S. economy, particularly in sectors like technology and health care, which make up a significant portion of its holdings. However, it may face challenges if interest rates rise, as small-cap companies often rely on borrowing to fund growth, or if economic conditions weaken, which could impact consumer spending and industrial activity. Regulatory changes in key sectors like financials or health care could also influence performance positively or negatively.
ABLS Top 10 Holdings
This small-cap fund leans heavily on U.S. health care and financial names, with Argan acting as the main engine—its strong run has been doing much of the heavy lifting. Oscar Health and Enova are also rising, adding momentum despite some underlying balance-sheet quirks. On the flip side, Collegium Pharmaceutical and Artisan Partners have been lagging, occasionally throwing sand in the fund’s gears. With a clear tilt toward domestically focused health care and financials, plus a dash of tech via Qualys, the ETF is concentrated but still spread across several small-cap niches.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Argan | 13.68% | $194.90K | $9.90B | 227.45% | 73 Outperform | |
| Oscar Health | 5.75% | $81.96K | $9.70B | 87.03% | 49 Neutral | |
| Enova International | 5.58% | $79.49K | $5.85B | 102.15% | 71 Outperform | |
| Collegium Pharmaceutical | 4.27% | $60.88K | $1.20B | 18.69% | 71 Outperform | |
| Healthcare Services | 3.87% | $55.10K | $1.73B | 66.09% | 72 Outperform | |
| Artisan Partners | 3.81% | $54.21K | $2.87B | -22.06% | 73 Outperform | |
| Harmony Biosciences Holdings | 3.62% | $51.57K | $2.16B | 14.80% | 81 Outperform | |
| Qualys | 3.30% | $46.95K | $5.22B | 7.09% | 78 Outperform | |
| Kontoor Brands | 3.25% | $46.24K | $4.70B | 24.30% | 66 Neutral | |
| Progyny | 3.10% | $44.12K | $2.37B | 44.20% | 79 Outperform |
ABLS Technical Analysis
Positive
―
Price Trends
21.33
Positive
20.08
Positive
20.12
Positive
Market Momentum
0.70
Negative
68.41
Neutral
52.57
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For ABLS, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 22.51, equal to the 50-day MA of 21.33, and equal to the 200-day MA of 20.12, indicating a bullish trend. The MACD of 0.70 indicates Negative momentum. The RSI at 68.41 is Neutral, neither overbought nor oversold. The STOCH value of 52.57 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ABLS.
ABLS Peer Comparison
Comparison Results
Performance Comparison
ABLS
Abacus FCF Small Cap Leaders ETF
23.39
2.44
11.65%
AIMS
Acuitas Small Cap Active ETF
―
―
―
BKSE
BNY Mellon US Small Cap Core Equity ETF
―
―
―
STXK
Strive 2000 ETF
―
―
―
RUSC
US Small Cap Equity Active ETF
―
―
―
SYZ
Lazard US Systematic Small Cap Equity ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents